{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T02:38:13Z","timestamp":1769049493537,"version":"3.49.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Anti-CD19\u2013directed chimeric antigen receptor (CAR) T-cell therapy yields durable remissions in up to 40% of patients with chemoresistant aggressive B-cell non-Hodgkin lymphoma (NHL), a group of patients expected only to survive on average 6 months. Although longer follow-up is needed to define durability, CD19 CAR T cells are demonstrating similar promise in other B-NHL subtypes such as mantle cell lymphoma and the indolent B-cell NHLs. This transformative therapy, however, remains hamstrung by its associated toxicities of cytokine release syndrome and immune effector cell\u2013associated neurotoxicity syndrome, as well as by mechanisms of resistance and relapse and accessibility. To address these limitations, studies are underway to investigate toxicity prevention and mitigation strategies and the development of safer CARs, combination strategies to overcome T-cell exhaustion and dual antigen targeting to combat antigen loss, and alternative cell sources to address cost and manufacturing inefficiencies and resolve issues surrounding T-cell fitness.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000509","type":"journal-article","created":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T07:13:30Z","timestamp":1616224410000},"page":"107-111","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Chimeric Antigen Receptor T Cells for B-Cell Lymphoma"],"prefix":"10.1097","volume":"27","author":[{"given":"Richard","family":"Newcomb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caron","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","year":"2019","journal-title":"N Engl J Med"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/bloodadvances.2019001026","article-title":"Patient-reported long-term quality of life after tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","year":"2020","journal-title":"Blood Adv"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","year":"2019","journal-title":"Lancet Oncol"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","year":"2020","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"bib8-20250621","first-page":"40","article-title":"Primary analysis of Zuma-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/refractory (r\/r) indolent non-Hodgkin lymphoma (iNHL)","volume":"136","year":"2020","journal-title":"Blood"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1084\/jem.167.2.582","article-title":"Single cell origin of bigenotypic and biphenotypic B cell proliferations in human follicular lymphomas","volume":"167","year":"1988","journal-title":"J Exp Med"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"e134612","DOI":"10.1172\/jci.insight.134612","article-title":"Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy","volume":"5","year":"2020","journal-title":"JCI Insight"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1182\/blood.V91.12.4708","article-title":"Follicular lymphomas contain a clonally linked but phenotypically distinct neoplastic B-cell population in the interfollicular zone","volume":"91","year":"1998","journal-title":"Blood"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/j.1582-4934.2009.00865.x","article-title":"Side population of a murine mantle cell lymphoma model contains tumour-initiating cells responsible for lymphoma maintenance and dissemination","volume":"14","year":"2010","journal-title":"J Cell Mol Med"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy","volume":"38","year":"2020","journal-title":"J Clin Oncol"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","year":"2014","journal-title":"Blood"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.1200\/JCO.2020.38.15_suppl.8008","article-title":"Interim analysis of ZUMA-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/refractory indolent non-Hodgkin lymphoma [published online May 20, 2020]","volume":"38","year":"2020","journal-title":"J Clin Oncol"},{"key":"bib16-20250621","first-page":"303ra139","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","year":"2015","journal-title":"Sci Transl Med"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","year":"2020","journal-title":"JCO"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","year":"2020","journal-title":"J Clin Oncol"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1182\/bloodadvances.2020002118","article-title":"Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies","volume":"4","year":"2020","journal-title":"Blood Adv"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","year":"2020","journal-title":"Blood Adv"},{"key":"bib22-20250621","article-title":"Real-world adverse events associated with CAR T-cell therapy among adults age \u226565 years","volume":"S1879-4068(20)30145-4","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","year":"2020","journal-title":"Nat Med"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","year":"2020","journal-title":"N Engl J Med"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000509","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T17:03:16Z","timestamp":1750525396000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000509","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}